Version of Specification with Markings to Show Changes Made

Page 1, paragraph 1:

The present application claims the benefit of provisional application U.S. Provisional Application No. 60/101,825, filed September 25, 1998, and U.S. Provisional Application No. 60/101,693, filed September 25, 1998, the contents of which is are incorporated by reference herein.

Page 14, Table 1

Table 1. Selected TV-markers amino acid sequences

TV-##	SEQ ID	Sequence
TV-35	.1	AKKYAKKEKAAKKAYKKEAKAKAAEAAAKEAAYEA
TV-45	2	AKKYAKKAKAEKAKKAYKAAEAKKAAKYEKAAAEKAAAKE- AAYEA
TV-56	3	AKKYAKKEKAYAKKAEKAAKKAEAKAYKAAEAKKKAEAKY- KAEAAKAAAKEAAYEA
TV-66	4	AKKYAKKEKAYAKAKKAEAKKAKAEAKKYAKAAKAEK- KEYAAAEAKYKAEAAKAAAKEAAYEA
TV-77	5	AKKYAKKEKAYAKKAEKAAKKAEAKAYKAAEAKKKAKAEA- KKYAKAAKAEKKEYAAAEAKYKAEAAKAAAKEAAYEA
TV-86	6	AKKYAKKEKAYAKKAEKAAKKAEAKAYKAAEAKKKAKAEA- KKYAKAAKAEKKEYAAAEAKYKAEAAKKAYKAEAAKAAAK- EAAYEA
<u>TV-109</u>	7	AKKYAKKAEKAYAKKAKAAKEKKAYAKKEAKAYKAAEAKK- KAKAEAKKYAKEAAKAKKEAYKAEAKKYAKAAKAEKKEYA- AAEAKKAEAAKAYKAEAAKAAAKEAAYEA

Page 56, paragraphs 1-2:

The present invention provides molecular weight markers for accurate determination of the molecular weight of glatinamer acetate and other copolymers. The present invention further provides a plurality of molecular weight markers for determining the molecular weight of glatinamer acetate and other copolypmers which display linear relationships between molar ellipticity and molecular weight, and between retention time and the log of the molecular weight.

The molecular weight markers also optimally demonstrate biological activity similar to glatiramer acetate orcorresponding or corresponding copolymers and can be used for treating or preventing various immune diseases. In addition, the subject invention provides pharmaceutical compositions for the treatment of immune diseases comprising a polypeptide having an identified molecular weight and an amino acid composition corresponding to glatiramer acetate or a terpolymer.